Comparative Pharmacology
Head-to-head clinical analysis: AUVI Q versus SUS PHRINE SULFITE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUVI Q versus SUS PHRINE SULFITE FREE.
AUVI-Q vs SUS-PHRINE SULFITE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic stimulation increases peripheral vascular resistance, reversing hypotension and improving coronary perfusion. Beta-adrenergic stimulation causes bronchodilation, positive chronotropic and inotropic effects, and vasodilation.
Epinephrine is a sympathomimetic catecholamine that acts as a non-selective agonist at all adrenergic receptors (α1, α2, β1, β2, β3). Its primary therapeutic effects include vasoconstriction (α1-mediated), bronchodilation (β2-mediated), and positive chronotropic/inotropic effects (β1-mediated).
0.3 mg intramuscularly into anterolateral thigh, repeated every 5-15 minutes as needed.
0.3-0.5 mg subcutaneously or intramuscularly every 15-20 minutes as needed for anaphylaxis. Maximum single dose: 0.5 mg.
None Documented
None Documented
The terminal elimination half-life of epinephrine is approximately 2–3 minutes when administered intravenously. After intramuscular injection, the half-life is extended to about 20–30 minutes due to slower absorption, providing a longer duration of therapeutic effect.
2 minutes (initial rapid phase), terminal half-life approximately 1-2 hours (alpha phase). Clinical context: Very short half-life necessitates continuous infusion for sustained effect.
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Renal excretion of metabolites accounts for the majority of elimination; less than 5% is excreted unchanged in urine.
Primarily renal excretion of metabolites (vanillylmandelic acid, metanephrine, and other conjugates); less than 2% excreted unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist